• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Retinal Degeneration - Pipeline Review, H2 2012 Product Image

Retinal Degeneration - Pipeline Review, H2 2012

  • ID: 2366303
  • December 2012
  • 48 pages
  • Global Markets Direct

Retinal Degeneration – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Retinal Degeneration - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Retinal Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Degeneration. Retinal Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinal Degeneration.
- A review of the Retinal Degeneration products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Retinal Degeneration Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Retinal Degeneration 7
Retinal Degeneration Therapeutics under Development by Companies 9
Retinal Degeneration Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Retinal Degeneration Therapeutics – Products under Development by Companies 15
Retinal Degeneration Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Retinal Degeneration Therapeutics Development 17
Targeted Genetics Corporation 17
Sigma-Tau S.p.A. 18
Santhera Pharmaceuticals Holding AG 19
to-BBB technologies BV 20
Genethon 21
China Shenghuo Pharmaceutical Holdings, Inc. 22
Retinal Degeneration – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
idebenone - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
levocarnitine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tgAAG76 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
rAAV2/4.hRPE65 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Leber’s Hereditary Optic Neuropathy Program - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Sh1002 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cyclic Nucleotide Analogue - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AAV2-ND4 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Retinal Degeneration Therapeutics – Drug Profile Updates 38
Retinal Degeneration Therapeutics – Discontinued Products 40
Retinal Degeneration Therapeutics - Dormant Products 41
Retinal Degeneration – Product Development Milestones 42
Featured News & Press Releases 42
Nov 16, 2012: Santhera Pharma Expects CHMP Opinion On MAA For Raxone In Early 2013 42
May 24, 2012: RetroSense Therapeutics Completes Pre-IND Meeting For RST-001 42
Jul 26, 2011: Catena Improves Sight For Patients With Inherited Blindness, Newcastle University Study Finds 43
Jul 22, 2011: EMA Accepts Santhera's Marketing Authorization Application Of Idebenone For Review In LHON 43
May 27, 2011: Data From Santhera's RHODOS Study To Be Presented At European Neurological Society 2011 Meeting 44
Dec 15, 2009: QLT Inc. Initiates Phase Ib Trial Study Of QLT091001 For The Treatment Of Leber Congenital Amaurosis (LCA) 44
Mar 12, 2009: QLT Announces Completion Of Phase Ia Safety Trial Of Its Synthetic Retinoid Product QLT091001 45
Oct 09, 2008: QLT Announces The Initiation Of A Phase I Trial Of Its Synthetic Retinoid Product QLT091001 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products Under Development for Retinal Degeneration, H2 2012 7
Products under Development for Retinal Degeneration – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Targeted Genetics Corporation, H2 2012 17
Sigma-Tau S.p.A., H2 2012 18
Santhera Pharmaceuticals Holding AG, H2 2012 19
to-BBB technologies BV, H2 2012 20
Genethon, H2 2012 21
China Shenghuo Pharmaceutical Holdings, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Retinal Degeneration Therapeutics – Drug Profile Updates 38
Retinal Degeneration Therapeutics – Discontinued Products 40
Retinal Degeneration Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Retinal Degeneration, H2 2012 7
Products under Development for Retinal Degeneration – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos